Phase 4
Completed N=21
Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients
Source: ClinicalTrials.gov NCT01502787 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcomePrimary: Forearm Blood Flow — 96; 105 ml/min
Summary
The purpose of this study is to determine if Nebivolol a) attenuates the angiotensin II (Ang II)-induced increase in oxidative stress, thereby attenuating Ang II-induced vasoconstriction; and b) attenuates sympathetic mediated vasoconstriction during exercise, thereby reducing functional skeletal muscle ischemia in hypertensive patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Forearm Blood Flow |
96; 105 | — |
| SECONDARY Blood Pressure During Exercise |
101; 103 | — |
| SECONDARY Blood Pressure During Angiotensin II Infusion |
114; 113 | — |
Eligibility Criteria
Inclusion Criteria
- Stage I hypertension (140-159/90-99 mmHg)
- Men and women age 18-65
Exclusion Criteria
- Congestive heart failure or coronary artery disease
- Blood pressure averaging >159/99 mmHg or resting heart rate 1.4 mg/dL
- Asthma or chronic obstructive pulmonary diseases
- Left ventricular hypertrophy by echocardiography or ECG
- Pregnancy
- Hypersensitivity to beta blockers, microbubble contrast agents, or angiotensin
- Any history of substance abuse (other than tobacco)
- Concomitant drug treatment which raises endogenous nitric oxide levels such as nitrates or phosphodiesterase V inhibitors (Viagra, Levitra, or Cialis)
- History of symptomatic bradycardia or heart block
Data sourced from ClinicalTrials.gov (NCT01502787). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.